Inflammation plays a key role in the initiation and progression of atherosclerosis but also in the pathophysiology of atheromatous plaque disruption and the development of acute coronary syndromes. Neopterin is a marker of inflammation and of immune system activation, it is synthesized by macrophages, that, once activated, release this substance. Indeed, in clinical evaluation of patients, measurements of plasma levels of neopterin are usually used to evaluate progression of viral infections, renal transplant rejection, severe systemic inflammatory diseases, nephritic syndrome and several autoimmune diseases. This mediator is able to induce a pro-atherothrombotic phenotype in cells of the coronary circulation. Recent data indicate that serum levels of neopterin are elevated in patients with coronary and peripheral artery disease and seem to be a prognostic marker for major adverse cardiovascular events. In particular, neopterin levels predict future major cardiac and vascular adverse events in patients presenting with chronic coronary artery disease, with acute coronary syndromes, and in those with critical limb ischemia. This renders this molecule a useful marker of atherosclerotic plaque activity, permitting the identification of the subjects at highest risk for major adverse cardiovascular events. In line with the above mentioned evidences, patients with high neopterin levels may require aggressive risk factor modification and intensive medical treatment irrespective of the severity of their coronary artery disease. This data suggest a potential clinical use of neopterin as a marker for disease activity in patients with cardiovascular disease.
REVIEW
In the last two decades, systematic studies have provided convincing evidence that inflammation plays a key role both in the initiation and progression of atherosclerosis [1, 2] . In particular, it has been evidenced that several well-known markers of systemic inflammation such as C-reactive protein (CRP), amyloid A, interleukin-6, matrix metalloprotease(s) and others, have an important role in triggering atherosclerotic plaque formation as well as its grown. Indeed, these molecules might also actively participate in plaque destabilization, finally leading to the occurrence of acute coronary syndromes [1, 2] .
Among these markers of inflammation, many studies have been focused on CRP. This inflammatory protein has been associated with increased cardiovascular risk in prospective epidemiological studies and it has been indicated as an important predictor of future cardiovascular adverse events [3] . In particular, patients with acute coronary syndromes and with elevated plasma levels of CRP have a significantly worse outcome as compared to patients with the same clinical presentation but with normal plasma levels of this protein [4] . Again, in healthy subjects, elevated CRP levels appear to be associated with the increased risk of develop future cardiovascular events [5] . Starting from these clinical observations, many studies have been designed to investigate the possible mechanism(s) of action of CRP, to clarify how this acute phase protein might be linked to cardiovascular events. Thus, it has been demonstrated that CRP, besides being a marker of inflammation, might exert direct effects on cells of the vessel wall directly involved in the pathophysiology of atherosclerosis and thrombosis such as endothelial and smooth muscle cells [6] .
In recent years, some epidemiological studies have indicated that plasma levels of another wellknown marker of inflammation, neopterin, were significantly elevated in patients with coronary artery disease (CAD) and with acute coronary syndromes [7] [8] [9] [10] .
Neopterin is a pteridine compound and a byproduct of the guanosine triphosphate-biopterin pathway [11] . It is synthesized by macrophages, that, once activated, release this substance. Since macrophage are actively involved in inflammatory mechanisms, neopterin is considered an index of macrophage activity thus representing an inflammatory marker [12] . Indeed, in clinical evaluation of patients, measurements of plasma levels of neopterin are usually used to evaluate progression of viral infections, renal transplant rejection, severe systemic inflammatory diseases, nephritic syndrome and several autoimmune diseases [13] . In the relatively recent point of view that ascribes to inflammation an important role in the pathophysiology of atherosclerosis, it is intriguing to consider for neopterin an active role within vulnerable plaque in the mechanism(s) responsible of acute coronary syndromes.
In the present report we give a brief overview of clinical, epidemiological evidences witnessing neopterin role in atherothrombotic disease, illustrating the possible pathophysiological mechanim(s) involved in the modulation of these phenomena.
Neopterin and Coronary Artery Disease
In recent years, some epidemiological studies have pointed out the association existing between increased plasma levels of neopterin, coronary artery disease and acute coronary syndromes [7] [8] [9] [10] .
It has been demonstrated by Zouridakis et al. that, in patients with stable angina, a close relationship exists between increased plasma neopterin concentrations and a faster progression of coronary atherosclerotic disease [10] . In another study performed in patients with similar clinical characteristics, Avanzas et al. demonstrated that elevated neopterin concentrations were an independent predictor of major adverse coronary events [14] . Again, in patients with history of hypertension, clinical symptoms of chest pain and without angiographic evidence of atherosclerotic disease, elevated plasma levels of neopterin seem to be associated with a higher incidence of cardiac adverse events over a 1-year follow up [15] .
Interestingly, also in women, which represent a patient population which benefit of the protective effects of estrogens, Garcia-Moll et al. showed that elevated plasma concentrations of neopterin were associated with the significant increase of cardiovascular risk [16] .
Particularly interesting was the observation that patients with unstable angina had higher measurable plasma levels of neopterin as compared to patients with stable angina [8] , suggesting that this molecule might play a role in plaque destabilization. In line with this hypothesis, the same researchers evidenced, in patients with unstable angina which underwent to coronary angiography, that neopterin plasma levels were correlated with the number of complex lesions, but not with extent and severity of coronary atherosclerosis [17] . These data permit to speculate that neopterin might be a marker of "activity" of coronary disease rather than a measure of its extent.
To date, the possible correlation between plasma levels of neopterin and the extent of coronary atherosclerosis is still debated, because results of different research groups were quite different. Specifically, Tanaka et al. evidenced that higher neopterin concentrations were directly correlated to the severity of coronary atherosclerosis in patients with stable angina pectoris [18] . On the contrary, Schumacher et al. observed that increased neopterin levels in patients with stable CAD, were not associated to the number or extent of coronary vessel involvement. They failed to identify any significant difference in neopterin levels between patients with minor and severe CAD [8] .
Neopterin levels are elevated also in patients with acute myocardial infarction. Gupta et al. showed that patients with unstable angina and myocardial infarction have significantly higher neopterin levels than the patients of the control group or subjects with previous AMI [7] .
As already described for CRP, several studies have demonstrated that neopterin might predict a worse outcome in patients with a first myocardial infarction. Specifically, Dominguez-Rodriguez et al. evidenced a strong association between neopterin levels and mortality in patients suffering acute myocardial infarction with ST-segment elevation [19] . Auer et al., in a retrospective study, observed that neopterin levels measured 72 hours after symptoms onset were significantly higher in patients with a clinical history of major cardiovascular events (MACE: cardiovascular death, recurrent AMI, stroke, hospital readmission for heart failure) during a 22 ± 3 months follow-up [9, 20] . On the contrary, patients with the same clinical presentation at baseline, but with low neopterin levels measured at the same time-point, did not develop MACE. This predictive value of neopterin may be observed also in patients with non-Q-wave myocardial infarction, as demonstrated by Van Haelst et al. [21] .
Neopterin and peripheral artery disease
Peripheral artery disease is usually associated with a higher frequency of concomitant coronary heart disease [22] . Thus, it is likely that neopterin levels are elevated also in patients with peripheral atherosclerosis. Indeed, Barani et al. evidenced that, in patients with critical limb ischemia (CLI), elevated levels of this inflammatory mediator are indicators of a more severe prognosis [23, 24] . In particular, this study reported neopterin to be an independent risk variable for death within 1 year in patients with CLI [23] . Moreover, the same group evidenced that neopterin levels correlated positively with echocardiographic signs of congestive heart failure [24] . In addition, patients with ischemic ECG modifications presented higher neopterin concentrations and 1-year mortality rate [24] .
According to the report by Barani, also Bertz et al. [25] reported that serum levels of neopterin, were elevated in patients with CLI. Specifically, these authors observed higher levels on neopterin in patients with CLI and diabetes as compared to patients with the same vascular disease but without diabetes. Moreover, they demonstrated a clear relationship between the extent of peripheral vascular disease, its severity and neopterin levels. In addition, to witness the correlation existing between peripheral and coronary artery disease, Erren et al. found higher neopterin levels in patients with peripheral arteries disease and concomitant coronary artery disease than in patients with coronary disease alone [26] .
Also in patients with atherosclerotic disease of carotid artery, neopterin levels are usually elevated [27] and, interestingly, these elevated plasma concentrations are associated with an increased rate of stroke or transient ischemic attack [28] .
Neopterin and artery disease: pathophysiology
Despite clinical observation described above that neopterin levels are strongly correlated to car-diovascular adverse events in patients with coronary as well as peripheral artery disease, the pathophysiology of these phenomena still remains largely incomplete. Indeed, as for CRP, the story goes from "bedside to the bench" because the researchers have focused their attention to the cardiovascular mechanisms of action of neopterin only in recent times.
Studies dealing with the potential effects of neopterin provided evidence that promotion of oxidative stress is a fundamental principle of neopterin's mode of action [29] . In particular, it has been recently demonstrated that neopterin is able to determine oxidative stress by means of iNOS induction [30] . Oxygen free radicals are highly reactive molecules with well-known effects on cardiovascular system [31] . Thus, it is very likely that neopterin might exert its effects on vessel wall cells thought this mechanism of action.
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fects on human cells of the coronary circulation shifting them towards a pro-atherothrombotic phenotype [32] . Specifically, in our study we have evidenced that this molecule plays an active role in the initiation of the atherosclerotic disease by inducing, in endothelial cells, the expression of two important Cellular Adhesion Molecules (CAMs) such as VCAM-1 and ICAM-1. These CAMs are responsible of attachment and trans-endothelial migration of leukocytes [33] and are known to be directly involved in the pathogenesis of atherosclerosis mediating many of the stages of the disease progression [33] . In addition, serum concentration of CAMs are strongly correlated with coronary artery disease [34] and with the risk of cardiovascular events [35] . Furthermore, neopterin is able to induce expression on endothelial cells of Tissue Factor (TF), the initiator of the extrinsic coagulation pathway, and trigger of intravascular thrombosis [36, 37] . These observations might have important pathophysiological consequences, since endothelial cells represent the interface between the vessel wall and the flowing bloodstream containing coagulation factors and leukocytes. These neopterin effects on coronary endothelial cells were mediated through oxygen free radicals production and activation of the transcription factor NF-κB. This transcription factor is present but inactive in the cytoplasm of many cells such as lymphocytes, monocytes, endothelial and smooth muscle cells. It seems to be activated by several stimuli during the atherosclerotic process and it is responsible of the expression of inflammatory proteins that actively participate in this process and might lead to plaque disruption and acute coronary events [38] . In particular, activation of NF-κB stimulates the promoter for TF [39] , for CAMs [40] as well as for Nitric Oxide genes [41] . Considering that NF-κB has been demonstrated to be activated in the peripheral monocytes [42] , as well as within the unstable plaques of patients with acute coronary syndromes [43] , the finding that neopterin induces TF and CAMs expression via activation of NF-κB might explain, at least in part, why patients with artery disease and elevated neopterin serum levels have a worse clinical outcome than patients with normal serum levels.
Taken together, these data permit to design an hypothetical mechanism of action in which activated monocytes/macrophages in atherosclerotic lesions significantly increase local neopterin levels; thus, they induce expression of ICAM-1 and VCAM-1 on endothelial cells in coronary circulation. Increased expression of CAMs may result in increase binding of T lymphocytes, platelets and other monocytes (that, once activated, further increase local neopterin concentration), key players in the atherosclerotic process. The endothelial activation causes expression of TF, promoting an "endothelial pro-thrombotic phenotype" and finally leading to the occurrence of acute coronary syndromes.
Conclusions
The studies reviewed have demonstrated that neopterin levels are an important predictor of future cardiac as well as vascular adverse events. In particular, neopterin levels predict future major cardiac and vascular adverse events in patients presenting with chronic coronary artery disease [8, 10, 14, 16] , with acute coronary syndromes [7-9, 17, 19-21] , and in those with CLI [23, 24] . Many of the above cited studies underline the strong association between high neopterin levels and complex atherosclerotic lesions but not with disease extension [8, 14, 16, 17] , giving account for the prognostic properties of neopterin. This renders this molecule a useful marker of atherosclerotic plaque activity, permitting the identification of the subjects at highest risk for MACE.
Several researchers have reported the beneficial effects of pharmacological intervention with statins in reducing cardiovascular disease risk [44, 45] . This evidence provides an adjunctive hint to the pathophysiology of plaque instability, suggesting that at least part of the benefit observed using these medications are related to their anti-inflammatory effects. Indeed, it has been demonstrated, in vitro, that neopterin effects on endothelial cells are significantly reduced by lovastatin [32] . In line with the Figure 1. -The inflammation play a role key in the pathogenesis of atherosclerosis. Activated monocytes/macrophages in atherosclerotic lesions significantly increase local neopterin levels. Neopterin stimulates cytoplasmatic oxygen free radical generation. OFRs activate nuclear transcription factor NF-κB. This transcription factor is responsible of mRNA transcription for Tissue Factor and Cellular Adhesion Molecules. Statins might reduce these neopterin effects by inhibiting OFRs production. OFRs: oxygen free radicals; TF: tissue factor; CAMs: cellular adhesion molecules.
above mentioned evidences, patients with high neopterin levels may require aggressive risk factor modification and intensive medical treatment irrespective of the severity of their coronary artery disease.
Taken together, observations from all the studies reviewed propose the existence of a strong link between high neopterin levels and cardiovascular risk profile, suggesting a potential clinical use of neopterin as a marker for disease activity in subject with cardiovascular disease. This could help in identifying patients who are at a higher risk of developing cardiovascular adverse events who might benefit from urgent preventive strategies exploitation or extensive diagnostic work-up, as well as actual therapy, depending from their co-morbidities. 
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